Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 6/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.56 |
| ▸ | GPR84 | Q9NQS5 | 7/20 | 0.52 |
| ▸ | PPARG | P37231 | 7/20 | 0.52 |
| ▸ | PPARD | Q03181 | 7/20 | 0.52 |
| ▸ | PPARA | Q07869 | 7/20 | 0.52 |
| ▸ | HDAC11 | Q96DB2 | 5/20 | 0.52 |
| ▸ | PTPN1 | P18031 | 3/20 | 0.52 |
| ▸ | TLR2 | O60603 | 2/20 | 0.52 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.52 |
| ▸ | FABP4 | P15090 | 2/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.52 |
| ▸ | SLC22A6 | Q4U2R8 | 1/20 | 0.52 |
| ▸ | SLC22A8 | Q8TCC7 | 1/20 | 0.52 |
| ▸ | MEN1 | O00255 | 1/20 | 0.52 |
| ▸ | ESR1 | P03372 | 1/20 | 0.52 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.52 |
| ▸ | PDE4A | P27815 | 1/20 | 0.52 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.52 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9451204 | 1.00 | — | — | |
| SCHEMBL16560498 | 1.00 | TSHR (0.56) | TSHRALDH1A1GPR84PPARGPPARD | |
| SCHEMBL10397317 | 1.00 | TSHR (0.56) | TSHRALDH1A1GPR84PPARGPPARD | |
| SCHEMBL11867093 | 1.00 | TSHR (0.56) | TSHRALDH1A1GPR84PPARGPPARD | |
| SCHEMBL13465735 | 1.00 | TSHR (0.56) | TSHRALDH1A1GPR84PPARGPPARD | |
| SCHEMBL7634467 | 0.97 | — | — | |
| SCHEMBL6537074 | 0.88 | — | — | |
| SCHEMBL20854579 | 0.82 | CES2 (0.52) | TSHRALDH1A1GPR84PPARGPPARD | |
| SCHEMBL20854578 | 0.82 | CES2 (0.52) | TSHRALDH1A1GPR84PPARGPPARD | |
| SCHEMBL20854580 | 0.82 | CES2 (0.52) | TSHRALDH1A1GPR84PPARGPPARD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 53 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6166173-A | Biodegradable polymers chain-extended by phosphates, compositions, articles and methods for making and using the same | GUILFORD PHARMACEUTICALS INC. (US) | 2000-12-26 | — | — | US | claimed |
| EP-2409569-B1 | Method for administering GLP-1 molecules | EMISPHERE TECH INC (US) | 2017-08-16 | — | — | EP | disclosed |
| US-20130023688-A1 | PHOSPHORUS-CONTAINING COMPOUNDS WITH POLYMERIC CHAINS, AND METHODS OF MAKING AND USING THE SAME | EISAI INC. (US) | 2013-01-24 | — | — | US | disclosed |
| US-8258255-B2 | Phosphorus-containing compounds with polymeric chains, and methods of making and using the same | EISAI INC. (US) | 2012-09-04 | — | — | US | disclosed |
| US-20100267924-A1 | Phosphorus-Containing Compounds with Polymeric Chains, and Methods of Making and Using the Same | EISAI INC. (US) | 2010-10-21 | — | — | US | disclosed |
| US-7674875-B2 | Phosphorus-containing compounds with polymeric chains, and methods of making and using the same | EISAI INC. (US) | 2010-03-09 | — | — | US | disclosed |
| US-20090247778-A1 | Star polymer such as of a polylactone based on a central phosphorus atom derived from phosphorus oxychloride (POCl3) or ethyl dichlorophosphate; biodegradable and/or biocompatible; sustained release drug delivery; reverse thermal gelation | EISAI CORPORATION OF NORTH AMERICA (US) | 2009-10-01 | — | — | US | disclosed |
| US-7479535-B2 | Phosphorous-containing compounds with polymeric chains, and methods of making and using the same | GUILFORD PHARMACEUTICALS, INC. (US) | 2009-01-20 | — | — | US | disclosed |
| US-7101568-B2 | Methods and compositions for treating solid tumors | GUILFORD PHARMACEUTICALS, INC. (US) | 2006-09-05 | — | — | US | disclosed |
| EP-1140028-B1 | BIODEGRADABLE POLY(PHOSPHOESTER) COMPOSITIONS FOR TREATING OVARIAN CANCER | GUILFORD PHARM INC (US) | 2005-11-23 | — | — | EP | disclosed |
| EP-1140028-A1 | METHODS FOR TREATING OVARIAN CANCER, POLY(PHOSPHOESTER) COMPOSITIONS, AND BIODEGRADABLE ARTICLES FOR SAME | GUILFORD PHARMACEUTICALS INC. (US) | 2001-10-10 | — | — | EP | disclosed |
| EP-1096957-A1 | METHODS AND REAGENTS FOR INTRAMUSCULAR DELIVERY OF NUCLEIC ACIDS | Johns Hopkins University School of Medicine (US) | 2001-05-09 | — | — | EP | disclosed |
| US-6166173-A | Biodegradable polymers chain-extended by phosphates, compositions, articles and methods for making and using the same | GUILFORD PHARMACEUTICALS INC. (US) | 2000-12-26 | — | — | US | disclosed |
| WO-2000057852-A2 | METHODS AND COMPOSITIONS FOR TREATING SOLID TUMORS | GUILFORD PHARMACEUTICALS, INC. (US) | 2000-10-05 | — | — | WO | disclosed |
| WO-2000041678-A1 | METHODS FOR TREATING OVARIAN CANCER, POLY(PHOSPHOESTER) COMPOSITIONS, AND BIODEGRADABLE ARTICLES FOR SAME | GUILFORD PHARMACEUTICALS INC. (US) | 2000-07-20 | — | — | WO | disclosed |
| WO-1999065531-A9 | POLYMERS FOR DELIVERY OF NUCLEIC ACIDS | UNIV JOHNS HOPKINS MED (US) | 2000-04-27 | — | — | WO | disclosed |
| EP-0971969-A1 | BIODEGRADABLE POLYMERS CHAIN-EXTENDED BY PHOSPHATES, COMPOSITIONS, ARTICLES AND METHODS FOR MAKING AND USING THE SAME | GUILFORD PHARMACEUTICALS INC. (US) | 2000-01-19 | — | — | EP | disclosed |
| WO-1999065531-A1 | POLYMERS FOR DELIVERY OF NUCLEIC ACIDS | JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE (US) | 1999-12-23 | — | — | WO | disclosed |
| WO-1998044020-A1 | BIODEGRADABLE POLYMERS CHAIN-EXTENDED BY PHOSPHATES, COMPOSITIONS, ARTICLES AND METHODS FOR MAKING AND USING THE SAME | GUILFORD PHARMACEUTICALS INC. (US) | 1998-10-08 | — | — | WO | disclosed |
| US-3953653-A | HALOGENATED HYDROCARBONS, ACIDS, HYPOHALOGENITES | PHILLIPS PETROLEUM COMPANY (US) | 1976-04-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130023688-A1 | PHOSPHORUS-CONTAINING COMPOUNDS WITH POLYMERIC CHAINS, AND METHODS OF MAKING AND USING THE SAME | PHOSPHO1, PLCG2, PPIP5K2 | TSHR 3222/4885ALDH1A1 4322/4885GPR84 3082/4885 |
| US-20090247778-A1 | Star polymer such as of a polylactone based on a central phosphorus atom derived from phosphorus oxychloride (POCl3) or ethyl dichlorophosphate; biodegradable and/or biocompatible; sustained release drug delivery; reverse thermal gelation | STARD3, CDKL3, OSBPL3 | TSHR 937/4885ALDH1A1 4166/4885GPR84 3163/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.